Literature DB >> 33737932

Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution.

Monica L Fernández-Quintero1, Katharina B Kroell1, Florian Hofer1, Jakob R Riccabona1, Klaus R Liedl1.   

Abstract

Characterizing and understanding the antibody binding interface have become a pre-requisite for rational antibody design and engineering. The antigen-binding site is formed by six hypervariable loops, known as the complementarity determining regions (CDRs) and by the relative interdomain orientation (VH-VL). Antibody CDR loops with a certain sequence have been thought to be limited to a single static canonical conformation determining their binding properties. However, it has been shown that antibodies exist as ensembles of multiple paratope states, which are defined by a characteristic combination of CDR loop conformations and interdomain orientations. In this study, we thermodynamically and kinetically characterize the prominent role of residue 71H (Chothia nomenclature), which does not only codetermine the canonical conformation of the CDR-H2 loop but also results in changes in conformational diversity and population shifts of the CDR-H1 and CDR-H3 loop. As all CDR loop movements are correlated, conformational rearrangements of the heavy chain CDR loops also induce conformational changes in the CDR-L1, CDR-L2, and CDR-L3 loop. These overall conformational changes of the CDR loops also influence the interface angle distributions, consequentially leading to different paratope states in solution. Thus, the type of residue of 71H, either an alanine or an arginine, not only influences the CDR-H2 loop ensembles, but co-determines the paratope states in solution. Characterization of the functional consequences of mutations of residue 71H on the paratope states and interface orientations has broad implications in the field of antibody engineering.
Copyright © 2021 Fernández-Quintero, Kroell, Hofer, Riccabona and Liedl.

Entities:  

Keywords:  Markov-state modes; antibodies; canonical clusters; molecular dynamics simulations; role of residue 71H

Year:  2021        PMID: 33737932      PMCID: PMC7960778          DOI: 10.3389/fimmu.2021.630034

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  64 in total

1.  PyEMMA 2: A Software Package for Estimation, Validation, and Analysis of Markov Models.

Authors:  Martin K Scherer; Benjamin Trendelkamp-Schroer; Fabian Paul; Guillermo Pérez-Hernández; Moritz Hoffmann; Nuria Plattner; Christoph Wehmeyer; Jan-Hendrik Prinz; Frank Noé
Journal:  J Chem Theory Comput       Date:  2015-10-14       Impact factor: 6.006

Review 2.  Conformations of immunoglobulin hypervariable regions.

Authors:  C Chothia; A M Lesk; A Tramontano; M Levitt; S J Smith-Gill; G Air; S Sheriff; E A Padlan; D Davies; W R Tulip
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

Review 3.  Thermodynamics of antibody-antigen interaction revealed by mutation analysis of antibody variable regions.

Authors:  Hiroki Akiba; Kouhei Tsumoto
Journal:  J Biochem       Date:  2015-05-07       Impact factor: 3.387

4.  Antibody framework residues affecting the conformation of the hypervariable loops.

Authors:  J Foote; G Winter
Journal:  J Mol Biol       Date:  1992-03-20       Impact factor: 5.469

5.  The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.

Authors:  Annemarie Honegger; Alain Daniel Malebranche; Daniela Röthlisberger; Andreas Plückthun
Journal:  Protein Eng Des Sel       Date:  2009-01-10       Impact factor: 1.650

Review 6.  Three-dimensional structure of antibodies.

Authors:  P M Alzari; M B Lascombe; R J Poljak
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

7.  Stability and CDR composition biases enrich binder functionality landscapes.

Authors:  Benjamin J Hackel; Margaret E Ackerman; Shanshan W Howland; K Dane Wittrup
Journal:  J Mol Biol       Date:  2010-06-09       Impact factor: 5.469

8.  Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex.

Authors:  Masaaki Adachi; Youji Kurihara; Hiroyuki Nojima; Mayuko Takeda-Shitaka; Kenshu Kamiya; Hideaki Umeyama
Journal:  Protein Sci       Date:  2003-10       Impact factor: 6.725

9.  CDR-H3 loop ensemble in solution - conformational selection upon antibody binding.

Authors:  Monica L Fernández-Quintero; Johannes Kraml; Guy Georges; Klaus R Liedl
Journal:  MAbs       Date:  2019-06-09       Impact factor: 5.857

10.  Hiding in plain sight: structure and sequence analysis reveals the importance of the antibody DE loop for antibody-antigen binding.

Authors:  Simon P Kelow; Jared Adolf-Bryfogle; Roland L Dunbrack
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

View more
  5 in total

1.  Nanobody Paratope Ensembles in Solution Characterized by MD Simulations and NMR.

Authors:  Monica L Fernández-Quintero; Eugene F DeRose; Scott A Gabel; Geoffrey A Mueller; Klaus R Liedl
Journal:  Int J Mol Sci       Date:  2022-05-12       Impact factor: 6.208

2.  Ensembles in solution as a new paradigm for antibody structure prediction and design.

Authors:  Monica L Fernández-Quintero; Guy Georges; Janos M Varga; Klaus R Liedl
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

3.  Communication pathways bridge local and global conformations in an IgG4 antibody.

Authors:  Thomas Tarenzi; Marta Rigoli; Raffaello Potestio
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

4.  CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies.

Authors:  Monica L Fernández-Quintero; Katharina B Kroell; Lukas J Grunewald; Anna-Lena M Fischer; Jakob R Riccabona; Klaus R Liedl
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

5.  The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles.

Authors:  Monica L Fernández-Quintero; Anna-Lena M Fischer; Janik Kokot; Franz Waibl; Clarissa A Seidler; Klaus R Liedl
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.